|Year : 2016 | Volume
| Issue : 6 | Page : 434-445
Identification of urinary proteins potentially associated with diabetic kidney disease
RK Marikanty1, MK Gupta2, SVB Cherukuvada1, SSS Kompella3, AK Prayaga4, S Konda1, RV Polisetty1, MM Idris1, PV Rao5, GR Chandak1, KV Dakshinamurty6
1 CSIR-Centre for Cellular and Molecular Biology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
2 CSIR-Centre for Cellular and Molecular Biology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana; Institute of Bioinformatics, International Technology Park, Bangalore, India
3 Department of Biochemistry, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
4 Department of Pathology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
5 Department of Endocrinology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
6 Department of Nephrology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
|Date of Web Publication||10-Nov-2016|
G R Chandak
CSIR-Centre for Cellular and Molecular Biology, Hyderabad - 500 007, Telangana
Source of Support: None, Conflict of Interest: None
Diabetic nephropathy (DN) is the most common cause of chronic kidney disease. Although several parameters are used to evaluate renal damage, in many instances, there is no pathological change until damage is already advanced. Mass spectrometry-based proteomics is a novel tool to identify newer diagnostic markers. To identify urinary proteins associated with renal complications in diabetes, we collected urine samples from 10 type 2 diabetes patients each with normoalbuminuria, micro- and macro-albuminuria and compared their urinary proteome with that of 10 healthy individuals. Urinary proteins were concentrated, depleted of albumin and five other abundant plasma proteins and in-gel trypsin digested after prefractionation on sodium dodecyl sulfate polyacrylamide gel electrophoresis. The peptides were analyzed using a nanoflow reverse phase liquid chromatography system coupled to linear trap quadrupole-Orbitrap mass spectrometer. We identified large number of proteins in each group, of which many were exclusively present in individual patient groups. A total of 53 proteins were common in all patients but were absent in the controls. The majority of the proteins were functionally binding, biologically involved in metabolic processes, and showed enrichment of alternative complement and blood coagulation pathways. In addition to identifying reported proteins such as α2-HS-glycoprotein and Vitamin D binding protein, we detected novel proteins such as CD59, extracellular matrix protein 1 (ECM1), factor H, and myoglobin in the urine of macroalbuminuria patients. ECM1 and factor H are known to influence mesangial cell proliferation, and CD59 causes microvascular damage by influencing membrane attack complex deposition, suggestive their biological relevance to DN. Thus, we have developed a proteome database where various proteins exclusively present in the patients may be further investigated for their role as stage-specific markers and possible therapeutic targets.
Keywords: Biomarker, diabetic nephropathy, liquid chromatography-tandem mass spectrometry, microalbuminuria, Orbitrap, urinary proteomics
|How to cite this article:|
Marikanty R K, Gupta M K, Cherukuvada S, Kompella S, Prayaga A K, Konda S, Polisetty R V, Idris M M, Rao P V, Chandak G R, Dakshinamurty K V. Identification of urinary proteins potentially associated with diabetic kidney disease. Indian J Nephrol 2016;26:434-45
|How to cite this URL:|
Marikanty R K, Gupta M K, Cherukuvada S, Kompella S, Prayaga A K, Konda S, Polisetty R V, Idris M M, Rao P V, Chandak G R, Dakshinamurty K V. Identification of urinary proteins potentially associated with diabetic kidney disease. Indian J Nephrol [serial online] 2016 [cited 2021 Nov 30];26:434-45. Available from: https://www.indianjnephrol.org/text.asp?2016/26/6/434/176144
| Introduction|| |
Type 2 diabetes mellitus (T2DM) is a global healthcare concern. About one-third of these patients are likely to develop diabetic nephropathy (DN), which is devastating in terms of clinical, economic, and ethical dimensions. India has a large number of diabetic patients that is expected to increase to about 69.9 million by 2025.  In addition, T2DM in Indians occurs at least a decade earlier than Europeans thus increasing the possibility of microvascular complications, especially of renal origin. The rising trend in the incidence of DN, requiring renal replacement therapy is an economic burden that cannot be met by most nations. There is a global need to implement diagnostic and management strategies, especially in India to reduce the risk factors for the development of DN.  Presence of albumin in the urine is considered predictive of development and progression of DN in T2DM patients,  but it is not a precise marker of DN. These facts indicate a need for an in-depth investigation of urine samples to identify novel protein candidates for clinical use as diagnostic and/or predictive biomarkers.
Several attempts have been made earlier to analyze urine samples to identify such biomarkers. The first human urinary proteome map generated about a decade back on acetone-precipitated urine samples from healthy subjects identified only 67 proteins.  Subsequently, various techniques have been used to investigate urine samples, but most of them have identified <100 proteins that are different between T2DM and DN patients. ,,,,, Taken together, a small number of proteins have been reported so far in the urine samples of DN patients and the majority of them are abundant plasma proteins that are repeatedly identified in different studies, thus compromising their utility as potential biomarkers. Recent advent of high throughput proteomic technologies has paved the way toward identification of large number of proteins in biological fluids such as blood, saliva, and urine. ,,,
In the background of above, we investigated urine proteome of T2DM patients with and without evidence of renal damage and compared it with normal individuals. We have identified novel proteins associated with different stages of diabetic kidney disease and also identified pathways that may be altered under these conditions.
| Materials and Methods|| |
Selection of patients
We recruited three groups of T2DM patients from Department of Nephrology at Nizam's Institute of Medical Sciences at Hyderabad, India [Table 1]. This included 10 patients each with normoalbuminuria, micro- and macro-albuminuria (urinary albumin = 3-30, 30-300, and >300 mg/dl, respectively). All patients met inclusion criteria of T2DM with and without history of proteinuria. The exclusion criteria were type 1 diabetes, history of hematuria, pregnant or lactating women, malignancy, and liver diseases. Ten healthy individuals from the same population, matched for age, sex, and socioeconomic status and in steady state conditions (defined as the lack of clinical events during the past 6 months to 1 year), were included as controls. They had normal renal function and blood pressure, no proteinuria, and normal urinary sediment and none of them were under any medication. All subjects signed written informed consent. Institutional Ethics Committees of both participating institutions approved the study.
|Table 1: Clinical and biochemical characteristics of the study population |
Click here to view
Collection, purification, and concentration of urine samples
Approximately, 50 ml of second-morning urine samples were collected using consistent procedures for sample collection, storage, and transportation (www.molmeth.org/protocols/MF43XA). The samples were centrifuged, and supernatant was stored at −80°C until further processing. Desalting and concentration of urinary proteins were done using 3 kDa molecular weight cut-off spin column (Amicon ultra-15 device, Millipore, Billerica, macroalbuminuria) by centrifugation at 4000 × g at 4°C. The protein content was estimated by the Bradford method.
Immunodepletion of urine samples of six abundant proteins
Equal amount of proteins from the concentrated urine samples from healthy individuals and patients from each group was pooled and processed for depletion as per manufacturer's instructions. Urine samples were pooled to avoid the heterogeneity of samples between the patients and ignore the individual differences. We pooled the samples to differentiating each group of patients rather than individuals. Briefly, human six immunoaffinity multiple affinity removal system (MARS column, 4.6 mm × 100 mm, Agilent Technologies, Santa Clara, CA, USA) was connected to a high-performance liquid chromatography system and equilibrated with Agilent buffer-A. We loaded 4 mg of urinary protein from each group onto the column to deplete six abundant proteins (albumin, IgG, IgA, antitrypsin, transferrin, and haptoglobin). Flow-through fractions were collected, concentrated and desalted using 5 kDa molecular weight cut-off spin column (Agilent, Palo Alto, CA). We determined the protein concentration using Bradford assay.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis prefractionation and tryptic digestion
Urinary proteins were reduced with 10 mM dithiothreitol at 60°C for 45 min, followed by alkylation with 50 mM iodoacetamide in 25 mM ammonium bicarbonate at room temperature for 1 h. Urinary proteins were prefractionated on 4-20% gradient precast sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels (Tris-Glycine midi gels, Invitrogen, CA). Based on molecular weight, the gel was divided into seven parts and sliced manually and destained with destaining solution (50% acetonitrile [ACN] in 50 mM ammonium bicarbonate). Gel pieces were dehydrated with 100% ACN, lyophilized, and digested with trypsin solution (Promega, Madison, WI, USA; 20 ng/μl) at 37°C for 16 h. Tryptic peptide mixtures were extracted using 0.3% trifluoroacetic acid in 50% ACN solution and lyophilized. A total of seven peptide fractions were made each for patient and control groups.
Liquid chromatography-tandem mass spectrometry analysis
We performed nanoflow electrospray ionization and tandem mass spectrometric analysis of peptide samples using linear trap quadrupole (LTQ)-Orbitrap Velos (Thermo Scientific, Bremen, Germany) interfaced with nanoflow liquid chromatography (LC) system. Each peptide fraction was separated on a Bio Basic C18 PicoFrit nanocapillary column (75 μm × 10 cm; New Objective, MA, USA) using a 90 min linear gradient of the mobile phase (5% ACN containing 0.1% formic acid [buffer-A] and 95% ACN containing 0.1% formic acid [buffer-B]) at a flow rate of 200 nl/min and analyzed on LTQ Orbitrap mass spectrometer. The voltage applied for ionization was 1.7 kV. Full scan MS spectra (from m/z 300-2000) were acquired after accumulation to a target value of 10−6 in the Fourier transform (FT). Resolution in the FT was set to r = 60,000 at MS level. The 20 most intense peptide ions with charge states ≥2 were sequentially isolated to a target value of 5000 and fragmented in linear ion-trap (IT) by collision-induced dissociation (CID) with normalized collision energy of 35% and wideband-activation enabled. The resulting fragment ions were scanned out in the low-pressure IT at the "normal scan rate" (33,333 amu/s) and recorded with the secondary electron multipliers. Ion selection threshold was set at 500 counts for MS/MS and the maximum allowed ion accumulation times were 500 ms (mille second) for full scans and 25 ms for CID-MS/MS measurements in the LTQ-Orbitrap Velos. An activation Q = 0.25 and activation time of 10 ms were used. Each fraction was run in duplicate resulting in generation of 56 raw files from all the four groups, which were searched against protein database.
Identification of proteins and analysis of urine proteome dataset in different groups
We analyzed the data files using SEQUEST search algorithm in Proteome Discoverer (Thermo Fisher Scientific, Beta Version 22.214.171.1249, Bremen, Germany) against the human International Protein Index database (version ipiHUMANv378fasta). Search parameters included trypsin as the enzyme with two missed cleavages allowed, oxidation of methionine as a dynamic modification and carbamidomethylation of cysteine as static modification. Precursor and fragment mass tolerance were set to 10 ppm and 0.8 Da respectively. The peptide and protein identifications were obtained using high peptide confidence and top one peptide rank filters. The false discovery rate (FDR) was calculated by enabling the peptide sequence analysis using a decoy database and high confidence peptide identifications were obtained by setting a target FDR threshold of 1% at the peptide level. The proteins thus obtained were analyzed for its gene ontological distribution such as biological processes, molecular function, cellular localization, and associated molecular pathways and cellular networks using GeneGo metacore software analysis (www.genego.com).
| Results|| |
In the present study, we used SDS-PAGE prefractionation followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach to generate and compare the proteome of urine samples of normal subjects and T2DM patients with and without renal complications. The workflow of the study is shown in [Supplementary Figure 1].
The clinical and biochemical characteristics of the study subjects are given in [Table 1]. The age and sex distribution of patients were comparable in all the groups. Diabetic patients (normoalbuminuria and microalbuminuria) had higher body mass index and waist to hip ratio as well as higher systolic and diastolic blood pressure compared to normal healthy subjects. We noted a progressive increase in serum creatinine, 24 h urinary total proteins, urinary albumin and a reduction in estimated glomerular filtration rate (all P < 0.001) from normoalbuminuria to micro- and macro-albuminuria group of patients indicating progressive decline in renal function with advanced disease. The glycemic control as indicated by glycosylated hemoglobin (Hb) and serum lipid levels also worsened from normoalbuminuria to micro- and macro-albuminuria group of T2DM patients. Thus, all patient groups exhibited metabolic abnormalities as well as evidence of progressive development of nephropathy from normoalbuminuria group to micro- and macro-albuminuria groups.
Proteome profiling of urine samples from diabetic and control groups
All urine samples were efficiently depleted of the six abundant proteins [Supplementary Figure 2]. Analysis of the MS/MS spectra on Proteome Discoverer using SEQUEST search engine against ipiHUMANv378.fasta database identified 1208, 1924, 1964, and 1752 peptides which mapped to 274, 505, 468, and 320 proteins in control, normoalbuminuria, micro- and macro-albuminuria groups, respectively [Supplementary Table 1 Table 2 Table 3 Table 4]. More than two-third of the proteins were identified with multiple peptides.
[Additional file 1]
[Additional file 2]
[Additional file 3]
[Additional file 4]
Cellular and functional classification of identified urinary proteins
We classified the identified proteins according to Gene Ontology, which allowed annotation of close to 75% proteins [Figure 1]. Based on sub-cellular localization, the majority of the proteins in the macroalbuminuria group were extracellular and membrane-related [43%; [Figure 1]a. Classification on the basis of molecular functions revealed that one-third fraction (33%) were proteins that bind sugar, polysaccharide, glycosaminoglycan, nucleic acids, etc., and a near equal fraction (28%) was involved in catalytic and enzyme regulatory activity [Figure 1]b. Based on biological activity, the majority of the proteins (34%) were noted to be involved in metabolic processes such as carbohydrate and lipid metabolism and others were involved in cellular and developmental processes, biological regulation, and immune response [Figure 1]c. Similar results were observed in other two diabetic groups [Figure 2]. Thus, the majority of the identified proteins belonged to membrane and extracellular class were functionally binding proteins and biologically involved in various metabolic processes.
|Figure 1: Gene ontology-based classification of urinary proteins identified in macroalbuminuria group. (a) Sub-cellular localization, (b) molecular function, and (c) biological process|
Click here to view
|Figure 2: Comparison of gene ontology-based classification of urinary proteins among different groups. (a) Sub-cellular localization, (b) molecular function, and (c) biological process|
Click here to view
Comparison of urine proteome profile of diabetic patient groups with the control group and among individual diabetic groups
On comparison of the proteome from each patient group independently with the controls, we detected 315, 294, and 218 proteins unique to normoalbuminuria, micro- and macro-albuminuria groups, respectively [Figure 3]. Further comparison among three diabetic groups identified 169, 129, and 132 proteins, respectively in normoalbuminuria, micro- and macro-albuminuria groups only [Figure 4] and [Supplementary Table 5 Table 6 Table 7].
|Figure 3: Venn diagram representing comparison of urinary proteins identified in various diabetic groups with the control group. Numbers in parentheses represent proteins identified in each group, whereas those within circle represent proteins unique to the specific group. The intersect region of the circles shows proteins common to two comparison groups|
Click here to view
|Figure 4: Venn diagram representing comparison of urinary proteome studies of all four groups. Numbers in parentheses represent proteins identified in each group, whereas those within circle represent proteins unique to the specific group. The intersect region of the circles shows proteins common to all diabetic groups|
Click here to view
[Additional file 5]
[Additional file 6]
[Additional file 7]
We detected the majority of proteins commonly reported in the urine of macroalbuminuria patients. This includes proteins such as hemopexin, zinc-α2 -glycoprotein, α-1-antichymotrypsin, α-1-microglobulin, α-2-HS-glycoprotein, afamin, apolipoprotein (apo) A-I, β-2-microglobulin, and Vitamin D binding protein. In addition, several novel proteins including extracellular matrix protein 1 (ECM1), complement factor H, myoglobin, kininogens, and galectin-3 were also identified. We detected more than 200 low molecular weight (LMW) proteins, of which many have so far not been reported in the urine of macroalbuminuria patients [Supplementary Table 4]. These include proteins such as histidine-rich glycoprotein, kallikrein, fibrinogen beta chain, α-2-antiplasmin, dipeptidyl peptidase 1, lumican, apo-F, and heat shock protein β-2.
We identified several proteins in microalbuminuria group including α-1-acid glycoprotein, α-1B-glycoprotein, α-2-HS-glycoprotein, basement membrane-specific heparan sulfate proteoglycan core protein, β-2-microglobulin, cystatin-B, and transthyretin, which are similar to a large fraction of proteins identified by Andersen et al.  In addition, 129 unique proteins such as calreticulin, cartilage intermediate layer protein, CD2-associated protein, guanylate cyclase activator 2B, tubulin β-2C chain, acyl-CoA-binding protein, fatty acid binding protein 1, gastricsin, and desmoglein-2 were also observed in the microalbuminuria group [Supplementary Table 6].
We identified 169 unique proteins in normoalbuminuria and several of them such as superoxide dismutase, α-L-fucosidase, complement factor B, galectin-3-binding protein, primary amine oxidase, matrix metalloproteinase-9, isoform five of prominin-1, mucin-6, tenascin XB, and annexin A5 have not been reported earlier [Supplementary Table 5]. We also identified reported proteins, which include N-acetyl-α-D-glucosaminidase, β2 -glycoprotein, retinol binding protein, transthyretin, α-1-microglobulin, zinc-α2 -glycoprotein, and E-cadherin in the urine of normoalbuminuria patients. ,
In addition to the unique proteins, we also observed proteins not present in healthy control group but present in all three diabetic groups and found that 53 proteins were common among three patient groups and were absent in the control group [Figure 4]. We observed that several proteins such as zinc-α2 -glycoprotein, α-1-microglobulin, α-2-HS-glycoprotein, β-2-microglobulin, transthyretin, apo A-I, and ceruloplasmin are excreted in all patients groups [Table 2]. This may be attributed to loss of negative charge and hyperfiltration of glomerular basement membrane in T2DM. These proteins might have some predictive values and need to study further to qualify for diagnosis of DN. Until that time, this is a descriptive study.
|Table 2: List of total proteins identified in all type 2 diabetes groups |
Click here to view
Furthermore, we compared normoalbuminuric with proteinuric (micro- and macro-albuminuria) individuals and found 303 proteins were unique to proteinuric group [Supplementary Table 8]. The identified proteins were including apo A-II, cathepsin-D, ephrin-B2, guanylin and superoxide dismutase (Cu-Zn). Even though we identified several novel proteins at this stage, this is discovery phase study, and more validations are required before implementing their clinical utility.
[Additional file 8]
We have also done an independent urinary proteomic study on nondiabetic chronic kidney disease (minimal change disease, membranous glomerulonephritis, focal segmental glomerulosclerosis, and lupus nephritis) and compared the DN proteome data. Those observations are very different and found 96 proteins unique to DN only [Supplementary [Table 9].
[Additional file 9]
Network and pathway analysis
We could map close to 80% of the identified proteome for different molecular and biological network pathways. Alternate complement and blood coagulation network pathways characterized by 25 and 20 proteins, respectively, were most significantly associated with the urine proteome dataset [Supplementary Figure 3]. Except CD59 glycoprotein, which was present in all urine samples, several proteins such as C3, C3a, C3b, iC3b, C3c, C3dg, factor D, C3bBb, C9, and membrane attack complex (MAC) proteins of the alternate complement pathway were identified only in diabetic urine samples irrespective of the extent of renal damage. However, proteins such as factor B, factor Ba, factor Bb, C6, C7, and C8 gamma proteins were detected both in micro- and macro-albuminuria groups while several other proteins of this pathway C5, C5a, C5b, factor H, C8α, and C8β proteins were exclusively observed in the macroalbuminuria patients [Supplementary Figure 3a]. We identified proteins such as antithrombin III, fibrinogen alpha, fibrin, bradykinin, kininogen, and protein C inhibitor of the blood coagulation pathway in all urine samples while several others such as alpha-1 antitrypsin, fibrinogen beta, and alpha-2 macroglobulin were present in all diabetic patients but not in normal subjects. Proteins such as coagulation factor X and XII, protein S, PLAU, plasminogen, SERPINF2, plasmin, and heparin cofactor two were found expressed only in macroalbuminuria subjects [Supplementary Figure 3b].
| Discussion|| |
Analysis of urine proteome is increasingly used for clinical investigation of various diseases. It is well known that tubulo-interstitial changes occur as frequently as glomerular involvement in the diabetic kidney and the disease usually progresses from normoalbuminuria to micro- and macro-albuminuria. , Currently, microalbuminuria is considered the best predictor of subsequent development of nephropathy in T2DM patients, but it is often induced by arterial hypertension or heart failure in older patients.  In addition, it has also been observed in the progression of some diabetic patients to chronic kidney disease without evidence of albuminuria. , Therefore, additional markers are needed to identify diabetic patients at a high risk of developing DN. In the present study, we generated urine proteome of control and all three diabetic groups with high confidence. Subsequent comparisons (a) between the control and diabetic groups and (b) among the diabetic groups have identified proteins associated with each diabetic group, which could be explored further for clinical utility.
Comparison with the published literature
Several studies have used various proteomic techniques to generate urinary proteome in DN but due to their limited sensitivity, the number of identified proteins is small. ,, To our knowledge, this is one of the high throughput proteomic studies that has identified large number of urinary proteins in well-defined clinical samples of T2DM patients with and without kidney complications. In earlier studies, Sharma et al. identified 99 significantly altered spots in the urine of DN patients by employing two-dimensional differential gel electrophoresis (2DE).  Using 2DE, matrix-assisted laser desorption/ionization time-of-flight MS (TOF) technique, Jain et al., identified five altered proteins in the urine of diabetic patients compared to control subjects.  In relatively recent studies on macroalbuminuria patients, Rao et al. identified 62 proteins using difference gel electrophoresis and LC-MS/MS approach  while Bellei et al. reported 54 proteins by 2DE and electrospray ionization-Q-TOF MS/MS analysis.  Compared to their urinary protein profile, we detected 273 proteins that were not reported by either of them [Supplementary Figure 4]. We found 34 proteins common with the dataset of Rao et al., of which 16 proteins had differential levels on comparison of controls and normoalbuminuria subjects. Similarly, 33 proteins were also reported by Bellei et al., of which six proteins were altered in macroalbuminuria patients [Table 3]. Interestingly, we also detected 11 of the 19 altered proteins reported in differential serum protein analysis of DN patients  [Supplementary Table 10]. Three proteins, pigment epithelium-derived factor, glutathione peroxidase, and apo E proteins that have been reported as potential serum markers were identified in the present study, suggesting their possible role as diagnostic markers for DN.
|Table 3: Details of urinary proteins identified in MA patients and common to earlier studies |
Click here to view
[Additional file 10]
Identification of reported proteins such as α2 -HS-glycoprotein precursor (fetuin A), zinc-α2 -glycoprotein, hemopexin, and Vitamin D binding protein in different diabetic groups adds strength to the results from this study. Fetuin A is the most potent circulating inhibitor of calcium phosphorus precipitation and thus contributes to vascular calcification in DN.  It is also an important mediator of insulin resistance, thus it is possible that in the presence of nephropathy, fetuin-A exacerbates insulin resistance and thus, worsens the pro-atherogenic milieu among T2DM patients. Zinc-α2 -glycoprotein has been reported as one of the most abundant urinary proteins in macroalbuminuria and also associated with glomerular lesions. ,,, Higher levels of plasma hemopexin have been reported in type 2 diabetes, and they are postulated to cause glomerular inflammation and proteinuria by altering glomerular filtration barrier. , Vitamin D binding protein has been consistently associated with type 2 diabetes, glucose intolerance, insulin secretion and/or resistance, and pregnancy associated-diabetes. ,,,, It is reported to be responsible for immunopathogenesis and progression of the DN. 
Identification of novel urinary proteins and their possible role
We also identified large number of novel proteins whose function is still not well understood. However, the majority of them belonged to the category of binding proteins and were involved in biological activities related to carbohydrate and lipid metabolism. Several unique proteins were exclusively detected in different diabetic groups. One such interesting protein identified only in macroalbuminuria was ECM1 that has been implicated in cell proliferation, angiogenesis, and differentiation. Hyperglycemia is known to stimulate ECM1 synthesis in mesangial and endothelial cells through generation of reactive oxygen species, and DN is characterized by excessive accumulation of extracellular matrix in the kidney. , Its relevance is further strengthened with identification of complement factor H, which is a member of the regulators of complement activation family and is associated with obesity and metabolic disorders.  Factor H along with adrenomedullin is known to inhibit glucose-induced over-expression of ECM1 in mesangial cells induced, and thus discharge renoprotective functions. Thus, ECM1 may act as a marker of glomerular and tubulointerstitial damage.
We also detected myoglobin in macroalbuminuria patients, which is known to circulate freely in diabetic patients. Uncontrolled diabetes may induce its glycation, which is known to stimulate increased generation of free radicals and consequent renal damage.  We identified both high and LMW kininogens, which are established cofactors for coagulation and inflammation and components of the kallikrein-kinin system (KKS). The KKS regulates podocyte apoptosis, and thus glomerular hemodynamics and tubular function.  Other proteins such as immunoglobulin k-light chains (KLC) and β-2-microglobulin increase in urine as a result of proximal tubular dysfunction. , Similarly, collagen fragments identified in early renal damage in T2DM patients may help in the prognosis and monitoring of DN. , Overall, it may not be unreasonable to speculate that urinary levels of LMW proteins may help in early diagnosis and work better than urine albumin levels in predicting risk of macroalbuminuria.
Of many novel proteins detected exclusively in microalbuminuria patients, CD2-associated protein (CD2AP) has interesting antecedents. A defective expression of CD2AP has been reported in DN and congenital nephrotic syndrome confirming its role in maintaining normal slit diaphragm function. ,, Even urinary mRNA levels for CD2AP are reported to be significantly higher in DN and positively correlated with urinary albumin excretion, blood urea nitrogen, and serum creatinine.  Another protein is cartilage intermediate layer protein, which is known to participate in extracellular matrix structure and remodeling and thus influence insulin sensitivity. 
We also identified many novel proteins such as KLC, transthyretin, and retinol binding protein in urine of normoalbuminuric individuals. The current assumption is that release of these proteins may be due to disturbance of tubular function in diabetes, and hence their importance is a matter of speculation.
Network pathway analysis of proteome dataset identifies stage-specific proteins
Network and pathway analysis of the urinary proteome identified alternative complement and blood coagulation as two major pathways likely to be involved in the pathogenesis of renal complications of type 2 diabetes. Identification of common complement factors in micro- and macro-albuminuria indicates their potential role in initiation of renal complications in type 2 diabetes patients. CD59 is known to restrict MAC assembly by interacting with the terminal complement proteins C8 and C9 and thus protect kidney from complement-mediated attacks. Inactivation of CD59 due to glycation makes kidneys susceptible to increased MAC deposition and contributes to extensive microvascular damage, development of atherosclerosis, and diabetic complications. , In fact, glycated human CD59 has been identified in urine of diabetic patients and correlates with the levels of glycated Hb.  Presence of CD59 in all the groups but absence of MAC in control group indicates loss of CD59 due to glycation and might predict development of kidney disease in diabetes. Subsequent progression to microalbuminuria or macroalbuminuria may depend on interaction of specific complement factors such as C5 and C8 groups, which control local pro-inflammatory response and MAC assembly.  These proteins and factor H were identified exclusively in macroalbuminuria patients, suggesting their importance as stage-specific markers. In addition to its influence on extracellular matrix, complement factor H is known to accelerate the destructive action of factor I, which is a regulator molecular of the alternative pathway for immune responses.
It was equally interesting to have similar observations in the blood coagulation pathway. Presence of fibrinogen beta, bradykinin, and alpha-1 antitrypsin indicates activated extrinsic and intrinsic coagulation pathways in diabetes. However, occurrence of clotting factors such as thrombin and fibrinogen in both micro- and macro-albuminuria suggests hypercoagulable state that is characteristic of renal complications of diabetes. Further progression to macroalbuminuria is related to dysregulation of balance between blood coagulation and fibrinolysis. This state is exemplified by exclusive expression of factor X that participates in the formation of prothrombinase complex, and that cleaves prekallikrein to kallikrein, which catalyzes bradykinin formation and of plasminogen, SERPINF2 which resulting in formation of protease-inhibitor complexes in the macroalbuminuric patients. Further quantitative analyses may help to understand whether their levels correlate with the intensity of renal damage.
This study has several strengths and few limitations. First, we used urine samples from well-characterized T2DM patients followed over last few years. Second, the analysis used the most sensitive tools, which allowed us to identify large number of proteins with high confidence. Finally, we identified several proteins, which were reported earlier in DN patients and thus built confidence in the overall urinary proteome dataset. One of the limitations is the absence of validation of these results and the lack of quantitative analysis of these proteins.
In spite of using very high throughput technology, we paved with few limitations. We pooled urine samples to overcome sample preparation and LC-MS/MS analysis costs. In the pooled samples, the biological variance between pools is reduced compared with individual samples, but practical consequence of this is that power could be reduced. As we did not validate our identifications, we cannot say that those proteins can be used as predictive biomarkers unless they are validated in large sample size.
In summary, this study reaffirms the role of several established proteins in the pathogenesis of DN and also identifies large number of novel proteins, specific to different stages of DN. We propose an important role of alternate complement and blood coagulation pathways, which fits with the currently existing hypothesis in the development of microvascular complications of diabetes. This study provides a resource useful for further exploration of these proteins as markers for various stages of diabetes.
The authors would like to thank all the study participants for their voluntary participation. Critical suggestions in mass spectrometric analysis from Dr. R. Nagraj, CCMB, Hyderabad are also gratefully acknowledged.
Financial support and sponsorship
The funds for this study were provided by the Council of Scientific and Industrial Research (CSIR), Ministry of Science and Technology, Government of India, India under XII 5-year Plan grant THUNDER (to GRC).
Conflicts of interest
There are no conflicts of interest.
| References|| |
Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. Diabetes Atlas. 3 rd
ed. Kortrijik (Heule), Belgium: International Diabetes Federation; 2006. p. 15-103.
Chacko B, Vincent L. Prevalence of diabetic nephropathy. In: Dakshinamurty KV, editor. Diabetic Kidney Disease: Clinical Update in Nephrology. India: Elsevier; 2011. p. 85-115.
Ben Ameur R, Molina L, Bolvin C, Kifagi C, Jarraya F, Ayadi H, et al.
Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant 2010;25:2866-75.
Thongboonkerd V, McLeish KR, Arthur JM, Klein JB. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 2002;62:1461-9.
Sharma K, Lee S, Han S, Lee S, Francos B, McCue P, et al.
Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 2005;5:2648-55.
Lafitte D, Dussol B, Andersen S, Vazi A, Dupuy P, Jensen ON, et al.
Optimized preparation of urine samples for two-dimensional electrophoresis and initial application to patient samples. Clin Biochem 2002;35:581-9.
Jain S, Rajput A, Kumar Y, Uppuluri N, Arvind AS, Tatu U. Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J Assoc Physicians India 2005;53:513-20.
Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, et al.
Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007;30:638-43.
Meier M, Kaiser T, Herrmann A, Knueppel S, Hillmann M, Koester P, et al.
Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications 2005;19:223-32.
Rossing K, Mischak H, Parving HH, Christensen PK, Walden M, Hillmann M, et al.
Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 2005;68:193-205.
Kim HJ, Cho EH, Yoo JH, Kim PK, Shin JS, Kim MR, et al.
Proteome analysis of serum from type 2 diabetics with nephropathy. J Proteome Res 2007;6:735-43.
Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E, et al.
Proteomic identification of salivary biomarkers of type-2 diabetes. J Proteome Res 2009;8:239-45.
Rao PV, Lu X, Standley M, Pattee P, Neelima G, Girisesh G, et al.
Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007;30:629-37.
Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, et al.
Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008;19:1283-90.
Andersen S, Mischak H, Zürbig P, Parving HH, Rossing P. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 2010;11:29.
Lapsley M, Flynn FV, Sansom PA. Beta 2-glycoprotein-1 (apolipoprotein H) excretion and renal tubular malfunction in diabetic patients without clinical proteinuria. J Clin Pathol 1993;46:465-9.
Riaz S, Alam SS, Srai SK, Skinner V, Riaz A, Akhtar MW. Proteomic identification of human urinary biomarkers in diabetes mellitus type 2. Diabetes Technol Ther 2010;12:979-88.
Goligorsky MS, Addabbo F, O'Riordan E. Diagnostic potential of urine proteome: A broken mirror of renal diseases. J Am Soc Nephrol 2007;18:2233-9.
Groop L, Mäkipernaa A, Stenman S, DeFronzo RA, Teppo AM. Urinary excretion of kappa light chains in patients with diabetes mellitus. Kidney Int 1990;37:1120-5.
Mykkänen L, Haffner SM, Kuusisto J, Pyorälä K, Laakso M. Microalbuminuria precedes the development of NIDDM. Diabetes 1994;43:552-7.
Thongboonkerd V. Study of diabetic nephropathy in the proteomic era. Contrib Nephrol 2011;170:172-83.
Rodriguez-Suarez E, Siwy J, Zurbig P, Mischak H. Urine as a source for clinical proteome analysis: From discovery to clinical application. Biochim Biophys Acta 2014;1844:884-98.
Bellei E, Rossi E, Lucchi L, Uggeri S, Albertazzi A, Tomasi A, et al.
Proteomic analysis of early urinary biomarkers of renal changes in type 2 diabetic patients. Proteomics Clin Appl 2008;2:478-91.
Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, et al.
Serum fetuin-A in nondialyzed patients with diabetic nephropathy: Relationship with coronary artery calcification. Kidney Int 2005;67:1070-7.
Kumar Y, Uppuluri NR, Babu K, Phadke K, Kumar P, Ballal S, et al
. Proteomics of renal disorders: Urinary proteome analysis by two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry. Curr Sci India 2002;82:655-63.
Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS, et al.
Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 2007;18:913-22.
Van Campenhout A, Van Campenhout C, Lagrou AR, Abrams P, Moorkens G, Van Gaal L, et al.
Impact of diabetes mellitus on the relationships between iron-, inflammatory-and oxidative stress status. Diabetes Metab Res Rev 2006;22:444-54.
Bakker WW, Borghuis T, Harmsen MC, van den Berg A, Kema IP, Niezen KE, et al.
Protease activity of plasma hemopexin. Kidney Int 2005;68:603-10.
Szathmary EJ. The effect of Gc genotype on fasting insulin level in Dogrib Indians. Hum Genet 1987;75:368-72.
Iyengar S, Hamman RF, Marshall JA, Majumder PP, Ferrell RE. On the role of Vitamin D binding globulin in glucose homeostasis: Results from the San Luis Valley Diabetes Study. Genet Epidemiol 1989;6:691-8.
Baier LJ, Dobberfuhl AM, Pratley RE, Hanson RL, Bogardus C. Variations in the Vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. J Clin Endocrinol Metab 1998;83:2993-6.
Hirai M, Suzuki S, Hinokio Y, Chiba M, Kasuga S, Hirai A, et al.
Group specific component protein genotype is associated with NIDDM in Japan. Diabetologia 1998;41:742-3.
Kuoppala T. Alterations in Vitamin D metabolites and minerals in diabetic pregnancy. Gynecol Obstet Invest 1988;25:99-105.
Nahman NS. Mesangial cell responses to high glucose-levels and the development of diabetic glomerulosclerosis. Nefrologia 1994;14:385-90.
Ha H, Lee HB. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology (Carlton) 2005;10 Suppl: S7-10.
Moreno-Navarrete JM, Martínez-Barricarte R, Catalán V, Sabater M, Gómez-Ambrosi J, Ortega FJ, et al.
Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes 2010;59:200-9.
Roy A, Sen S, Chakraborti AS. In vitro
nonenzymatic glycation enhances the role of myoglobin as a source of oxidative stress. Free Radic Res 2004;38:139-46.
Riad A, Zhuo JL, Schultheiss HP, Tschöpe C. The role of the renal kallikrein-kinin system in diabetic nephropathy. Curr Opin Nephrol Hypertens 2007;16:22-6.
Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C. Beta-2 microglobulin in renal disease. J Am Soc Nephrol 1998;9:1723-35.
Alkhalaf A, Zürbig P, Bakker SJ, Bilo HJ, Cerna M, Fischer C, et al.
Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010;5:e13421.
Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R, et al.
Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004;65:2193-200.
Li C, Ruotsalainen V, Tryggvason K, Shaw AS, Miner JH. CD2AP is expressed with nephrin in developing podocytes and is found widely in mature kidney and elsewhere. Am J Physiol Renal Physiol 2000;279:F785-92.
Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, et al.
Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999;286:312-5.
Zheng M, Lv LL, Ni J, Ni HF, Li Q, Ma KL, et al.
Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy. PLoS One 2011;6:e20431.
Lehr S, Hartwig S, Lamers D, Famulla S, Müller S, Hanisch FG, et al.
Identification and validation of novel adipokines released from primary human adipocytes. Mol Cell Proteomics 2012;11. Doi: 10.1074/mcp.M111.010504.
Qin X, Goldfine A, Krumrei N, Grubissich L, Acosta J, Chorev M, et al.
Glycation inactivation of the complement regulatory protein CD59: A possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004;53:2653-61.
Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, et al.
Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res 2009;104:550-8.
Acosta J, Hettinga J, Flückiger R, Krumrei N, Goldfine A, Angarita L, et al.
Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A 2000;97:5450-5.
Gasque P. Complement: A unique innate immune sensor for danger signals. Mol Immunol 2004;41:1089-98.
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
||The complement pathway: New insights into immunometabolic signalling in diabetic kidney disease
| ||Sih Min Tan, Matthew Snelson, Jakob A Østergaard, Melinda T Coughlan |
| ||Antioxidants & Redox Signaling. 2021; |
|[Pubmed] | [DOI]|
||Complement factor B in high glucose–induced podocyte injury and diabetic kidney disease
| ||Qingmiao Lu, Qing Hou, Kai Cao, Xiaoli Sun, Yan Liang, Mengru Gu, Xian Xue, Allan Zijian Zhao, Chunsun Dai |
| ||JCI Insight. 2021; 6(19) |
|[Pubmed] | [DOI]|
||Urinary proteins detected using modern proteomics intervene in early type 2 diabetic kidney disease – a pilot study
| ||Alina Golea-Secara, Cristian Munteanu, Mirela Sarbu, Octavian M Cretu, Silvia Velciov, Adrian Vlad, Flaviu Bob, Florica Gadalean, Cristina Gluhovschi, Oana Milas, Anca Simulescu, Maria Mogos-Stefan, Mihaela Patruica, Ligia Petrica, Alina D Zamfir |
| ||Biomarkers in Medicine. 2020; 14(16): 1521 |
|[Pubmed] | [DOI]|
||The development and clinical applications of proteomics: an Indian perspective
| ||Khushman Taunk, Bhargab Kalita, Vaikhari Kale, Venkatesh Chanukuppa, Tufan Naiya, Surekha M. Zingde, Srikanth Rapole |
| ||Expert Review of Proteomics. 2020; 17(6): 433 |
|[Pubmed] | [DOI]|
||Curcumin alleviates diabetic nephropathy via inhibiting podocyte mesenchymal transdifferentiation and inducing autophagy in rats and MPC5 cells
| ||Qiudi Tu, Yiwen Li, Juan Jin, Xinxin Jiang, Yan Ren, Qiang He |
| ||Pharmaceutical Biology. 2019; 57(1): 778 |
|[Pubmed] | [DOI]|
||Molecular Network Analysis of the Urinary Proteome of Alzheimer’s Disease Patients
| ||Yumi Watanabe, Yoshitoshi Hirao, Kensaku Kasuga, Takayoshi Tokutake, Yuka Semizu, Kaori Kitamura, Takeshi Ikeuchi, Kazutoshi Nakamura, Tadashi Yamamoto |
| ||Dementia and Geriatric Cognitive Disorders Extra. 2019; 9(1): 53 |
|[Pubmed] | [DOI]|